Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
9.00
+0.40 (4.65%)
At close: Nov 6, 2026, 4:00 PM EST
8.95
-0.05 (-0.56%)
After-hours: Nov 6, 2026, 7:59 PM EST
Capricor Therapeutics Employees
Capricor Therapeutics had 231 employees as of December 31, 2025. The number of employees increased by 71 or 44.38% compared to the previous year. That makes Capricor Therapeutics the 25,731st largest employer in the world and 3,276th in the United States.
Employees
231
Change (1Y)
71
Growth (1Y)
44.38%
Revenue / Employee
n/a
Profits / Employee
-$560,245
Market Cap
523.25M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 231 | 71 | 44.38% | 231 | 0 |
| Dec 31, 2024 | 160 | 58 | 56.86% | 160 | 0 |
| Dec 31, 2023 | 102 | 28 | 37.84% | 101 | 1 |
| Dec 31, 2022 | 74 | 26 | 54.17% | 74 | 0 |
| Dec 31, 2021 | 48 | 22 | 84.62% | 48 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Valneva SE | 620 |
| REGENXBIO | 371 |
| Neurogene | 131 |
| Surrozen | 44 |
| DiaMedica Therapeutics | 35 |
| Ovid Therapeutics | 23 |
| Entera Bio | 22 |
CAPR News
- 5 days ago - Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10 - GlobeNewsWire
- 4 weeks ago - Capricor Therapeutics Transcript: Study result - Transcripts
- 4 weeks ago - Capricor Therapeutics Press release: Study result - Filings
- 4 weeks ago - Capricor Therapeutics Slides: Study result - Filings
- 4 weeks ago - Capricor Therapeutics call buyer realizes 94% same-day gains - TheFly
- 4 weeks ago - Roth sees second FDA panel as possibility for Capricor - TheFly
- 4 weeks ago - H.C. Wainwright sees complete response letter as most likely for Capricor - TheFly
- 4 weeks ago - Capricor announces open-label extension data for Deramiocel - TheFly